Rachel shares her journey from academic science into biotech leadership, reflecting on the pivotal moments that shaped her career - from early setbacks at university to working on T‑cell therapies that reached patients, and ultimately stepping into a first‑time CEO role. We discuss Pan Cancer T’s work developing next‑generation T‑cell therapies for solid tumours, and the challenges of translating complex science into the clinic.

She also reflects on confidence, resilience, and why saying yes to opportunities before you feel ready has been a defining theme throughout her career.

Ignacio shares his journey from Madrid to the Pasteur Institute, Stanford and Dundee, and now into biotech entrepreneurship. We talk about his work regenerating the thymus to rejuvenate the immune system, the science that inspired TECRegen, and the emerging opportunities in healthy ageing and immunotherapy.

He also reflects on navigating academia, the importance of resilience, why understanding “how the game is played” matters for early scientists, and what ultimately drew him from a successful academic career into building companies.

Sarah shares her journey from early lab work to leading translational science on a first in class neurodegeneration programme. We talk about the serendipity that shaped her career, the importance of early hands-on experience, and how redundancies opened unexpected doors.

Sarah reflects on leadership; from learning to give difficult feedback, to the responsibility that comes with shaping people’s day to day wellbeing, to the power of listening when managing teams. She also discusses adapting to biotech’s fast pace, navigating uncertainty, and the mindset needed to thrive in a small, mission driven environment.

We explore his transition from academia to industry, the lessons he learned building discovery platforms and leading translational programs, and how embracing storytelling and stakeholder alignment shaped his leadership approach.

Jonathan also takes us inside the creation of FireCyte - from reimagining the retina as a window into neurodegeneration to navigating an early scientific pivot that reshaped the company’s direction. His experience is a compelling reminder that breakthrough progress often starts with challenging assumptions and following the data.

After years immersed in structural biology and membrane protein folding, Eline realised she wanted her work to have real‑world impact. That shift pulled her out of academia, into translational science, and eventually into founding AAB Therapeutics - a company engineering extracellular vesicles to solve one of oncology’s biggest challenges: getting drugs where they need to go.

In this conversation, Eline shares the turning points that shaped her path, discussing the importance of curiosity, timing, and daring to step into the unknown - even when the success rate is small and the learning curve is steep.

A brilliant episode for anyone considering a move from academia into Biotech, or thinking about building something of their own.

Marc shares his journey from physics undergraduate to Biotech leader, and how a love of problem‑solving gradually drew him from yeast genetics into human disease and ultimately into drug development. After a decade in big pharma working on antibody–drug conjugates, he steps into Biotech leadership, first at Mersana and now at Alphina, where he’s pioneering a new class of ADCs built around NAMPT inhibition.

Along the way, Marc reflects on choosing industry without having a clear plan, understanding what makes a role the right fit, and why being truly data‑driven is one of the most important habits a scientist can develop.

An open, forward‑looking conversation about evidence, judgment and the momentum that comes from backing the right ideas at the right time.

Now VP of Musculoskeletal at Edgewise Therapeutics, Roxana shares the pivotal moments that shaped her journey: from her early days coordinating clinical trials in Texas, to building a name for herself in global pharma, and ultimately returning to her passion for muscular dystrophies.

In this episode of Careers in Discovery, we talk ambition, adaptability, and the importance of knowing what you want - even before you know how to get it.

Peter didn’t follow the typical founder path. After a long and successful career in big pharma R&D and business development, he made the leap into Biotech with a mission: to unlock the potential of transcription factors in treating neurodegenerative diseases. What followed was a complete mindset shift - from structure and scale to agility and risk. 

In this episode, Peter shares the thinking behind Scripta’s unique approach to drug discovery, how his experience at Sanofi and AstraZeneca shaped his leadership style, and why failure, iteration, and clarity of purpose are more important now than ever. 

Now VP of Technical Operations at Ottimo Pharma and co-founder of Sunflower Therapeutics, Kathryn’s career has been shaped by a relentless curiosity, a deep commitment to patient access, and a willingness to step into the unknown. She shares her journey from building perfusion bioreactors in grad school, to leading global CMC teams, to launching portable manufacturing units for biologics in the developing world. 

In this conversation, Kathryn reflects on lessons in leadership, mentorship, and integrity - from creating a calm, learning-focused culture to knowing when to walk away. She talks openly about imposter syndrome, what it really takes to transition into executive roles, and how entrepreneurship, like science, is best approached as an experiment. 

Now CEO of Evogene, Ofer shares how he moved from CFO to spinning out a company at the intersection of AI and biology, building platforms to discover small molecule therapeutics and agricultural innovations. He reflects on leading through uncertainty, what makes a strong Biotech culture, and why staying focused on real-world problems is essential to innovation. 

Evogene’s evolution is far from over, but Ofer’s story offers a rare and thoughtful look into the blend of science, business and humanity that drives Biotech forward. 

Now CEO of Spark Therapeutics and SVP at Roche, Sylke joins us on Careers in Discovery to share her journey from academia into Biotech, how Spark pioneered the world’s first FDA-approved directly administered gene therapy, and what it means to build the next generation of treatments - and the company culture to deliver them. 

She reflects on what it takes to lead through risk and uncertainty, how to balance scientific ambition with operational focus, and why authenticity and clarity are at the heart of impactful leadership. 

An inspiring conversation with a scientist-turned-CEO who’s still pushing boundaries and redefining what’s possible in genetic medicine. 

In this episode of Careers in Discovery, we’re joined by Federico Paoletti, CEO & Co-founder of Exogene, to find out.

Federico shares the story of how he went from a PhD in cancer biology to co-founding an Oxford-based immuno-oncology Biotech, working at the intersection of AI and protein engineering to develop personalised T-cell engager therapies. He talks about why he left academia despite loving science, what “high agency” really means in a Biotech startup, how to win partnerships, funding, and talent with no track record, and how curiosity - and trust - shaped Exogene’s culture from the very beginning.

If you're thinking about the leap into Biotech entrepreneurship, or flexing your leadership muscle in a startup setting, Federico’s journey will inspire you to go after the bold ideas - and find the people who will build them with you.

After 6 years and almost 200 episodes of Careers in Discovery, Singular CEO Tom Froggatt is passing the torch to a new host - and we're delighted to introduce Tyler Olding.

In this episode, the tables have turned, and the transition begins with - for the first time - an interview with Tom himself. Listen in to learn more about the brilliant career that has been behind Careers in Discovery, and the exciting times ahead for Tom.

-------------------------------------------------------------------------------------------------------------------------------

To download your free eBook, click the link here: The Global Hiring Blueprint

In this episode, Samir shares the personal and scientific journey that led to founding HAYA Therapeutics, a Biotech trailblazing an entirely new approach to treating common and chronic diseases. He explains how HAYA builds backwards from unmet patient needs, and forwards with a first-principles view of biology - putting the cell, not the target, at the centre of drug discovery.

This is a story about biology, yes - but it’s also about clarity, courage, and commitment to a new model of Biotech.

In this episode of Careers in Discovery, Rafal shares the journey that’s taken him from medical school in Poland to leading R&D efforts across UCB, Roche, and now Angelini. Along the way, we explore his deep commitment to neuroscience, the lessons of building research teams across academia, biotech, and pharma, and the transformation taking place at Angelini - from a 100-year-old company into a focused innovator in brain health.

We dive into why Angelini is investing in both cutting-edge science and public awareness, how Rafal made the leap from academia to industry, and what he looks for in people when building high-performing teams. He also reflects on the value of ambition, cultural perspective, and scientific humility when navigating a career in life sciences.

Martin shares his journey from pharmacologist to global R&D executive, with leadership roles at Pfenex, Recursion, AstraZeneca, and Stoke Therapeutics. Now at iBio, he leads a company developing gene therapies for rare diseases - while applying lessons from decades of drug development to a new generation of science.

We talk about the power of simplicity in communication, why leaders need to create space for science to breathe, and how to build R&D teams that are lean, smart, and focused on what matters most.

Erica shares how Geneoscopy is transforming gastrointestinal health with a platform that uses RNA biomarkers from stool samples to diagnose, monitor, and help prevent colorectal cancer and other GI diseases. She talks about the inspiration behind the company, building a patient-friendly alternative to colonoscopy, and why early detection is key to changing outcomes in colorectal cancer.

We also dive into Erica’s journey from MD-PhD student to entrepreneur, the challenges of shifting from product development to commercialization, and how she navigates the balance of leadership, family, and growth in a dynamic start-up environment.

Michael leads two innovative companies - one pioneering single-cell and stem cell handling technologies, the other developing early diagnostics for osteoporosis and bone metastasis. He shares his journey from chemist to Biotech entrepreneur, what he learns building capital-efficient businesses, and why staying close to the science keeps leadership challenging and rewarding.

We talk about the realities of being a hands-on CEO in small companies, the importance of speed and execution in a crowded market, and how Michael uses communication to build trust and alignment within his teams. He also reflects on the evolving Biotech funding landscape, lessons from scaling multiple ventures, and why embracing the unknown is key to turning breakthrough ideas into successful products.

Paulo shares his journey from neurology and academia into big pharma and now Biotech, reflecting on what he learns along the way. He talks about Xaira’s bold mission to use AI not just to speed up drug development, but to rethink how we do it entirely - overcoming human limitations in how we explore biology.

We also discuss why he leaves a successful career in pharma for the high-risk world of startups, how he stays optimistic in the face of failure, and what it really takes to build a company that’s aiming to change the game.

A thoughtful conversation with a leader bringing deep experience - and fresh perspective - to the future of drug discovery.

Tim shares his journey from early days as a medicinal chemist at Merck to a career spanning business development, CEO roles, and now chairing multiple early-stage Biotech companies. He talks about the shift from operator to portfolio leader, how he evaluates new opportunities, and why capital efficiency is a critical part of Biotech success - especially in the current market.

We also dive into Tay’s approach to doing more with less, how Concr is applying AI to reshape precision oncology, and what Tim looks for in founding teams. Along the way, he reflects on the value of learning from setbacks, building trust with investors, and why simplicity, storytelling, and timing make all the difference.

In this episode of Careers in Discovery, Ashley shares her journey from exotic animal vet to cancer biology PhD, and how that unique background leads her to explore biology through a completely different lens. She talks about the science behind Fauna’s work - how hibernating squirrels, among other species, reveal new insights into heart failure, obesity, and more - and how the company translates those discoveries into real therapeutic programs.

Ashley also reflects on what it means to build a platform company as a non-traditional founder, the challenges of raising capital for a truly novel idea, and why she believes in running a company built on trust, focus, and adaptability.

In this episode of Careers in Discovery, Søren shares his journey from chemical engineer to Biotech CEO, including leadership roles in R&D, commercial strategy, and company-building across Europe. He talks about learning by doing, transitioning from large pharma to start-up environments, and what it really takes to turn a scientific platform into a viable business.

We also explore the promise of exosomes as a new therapeutic modality, the realities of raising investment in a tough market, and why surrounding yourself with the right people - and staying curious - makes all the difference.

Remi shares his journey from academic research to building companies, the lessons he learned at Unity Biotechnology, and how Arda is using single-cell sequencing and targeted antibodies to eliminate disease-driving cells in chronic conditions.

We talked about the leap from scientist to founder, applying oncology tools beyond cancer, and why curiosity and risk-taking go hand in hand in Biotech.

Markus takes us behind the scenes of Autolus’ journey from a UCL spinout to a commercial-stage Biopharma company, offering a rare look at how quality underpins every part of the drug development lifecycle. From working across GMP and GCP to collaborating with regulators on novel therapies, Markus shares what it means to lead quality in a fast-moving, high-growth Biotech business.

We also explore Markus’ personal journey - from pharmacist to QP, and from the NHS to senior leadership - guided by a passion for learning, a commitment to patient safety, and a belief in empowering his team through empathy and integrity.

If you're curious about CAR-T, what quality looks like in a next-gen therapy company, or how to build a meaningful leadership career without a traditional plan, this episode is not to be missed.

We explore the pioneering work Vicebio is doing on multi-pathogen respiratory vaccines using molecular clamp technology, including how their approach could reduce the number of injections needed while improving vaccine stability and access in low-resource settings.

Pascal also reflects on his rich and varied career, from molecular biology and immunology to regulatory affairs, quality systems, and digital transformation. Along the way, he shares lessons on navigating major career transitions, leading without deep technical expertise, and how curiosity, values, and a willingness to take up space have shaped his path.

In this episode, Lalit shares how his love for chemistry led him from a PhD in organic synthesis to leading cutting-edge drug discovery programs that reached clinical trials. Now the founder and CEO of a stealth-mode company tackling the data gap in AI-driven drug design, he reflects on the lessons of building small, high-impact teams, the importance of lifelong learning, and why good storytelling is as essential as good science.

We also dive into the realities of building a Biotech from scratch, the role of luck (and preparation), and the power of collaboration across disciplines.

Jelena shares her fascinating journey from genetics researcher to founder and start-up builder, including the lessons she learned from creating seven businesses across life sciences, tech, and even live entertainment. She opens up about her transition from academia to entrepreneurship, the importance of testing ideas early with customers, and why stepping away from a company can sometimes be the right choice.

We also talk about embracing curiosity, building businesses that align with your passions and strengths, and how finding the right personal fit is key to both success and happiness.

In this episode of Careers in Discovery, Lars shares his journey from medicinal chemist to Biotech CSO, the lessons he learned building a company from scratch, and why taking the leap into Biotech offered him the chance to have real impact. He also talks about the science behind iOnctura’s approach, how focusing on quality of life - not just survival - is shaping the future of oncology, and why every founder needs a plan B.

Juozas joined us to talk about his unconventional journey from computer science into the world of life sciences, how a chance meeting with an epigenetics professor changed his career path, and the story behind founding VUGENE.

We also discussed the transformative impact of AI and machine learning on omics data, the realities of building a company from scratch, and why hiring that first team member is one of the scariest - but most rewarding - moments for any founder.

This is a conversation about creativity, resilience, and building bridges between technology and biology.

Mirko shares how a passion for chemistry and biology sparked his journey into drug discovery, and how his training in pharmacy gave him the unique ability to translate across scientific disciplines. He takes us through the ups and downs of building PerioTrap, from the science behind their microbiome-preserving approach to gum disease, to winning funding competitions, to a chance investor encounter that doubled their seed round.

We also talk about resilience in Biotech, the realities of raising money for an overlooked therapeutic area, and why Mirko believes patience, curiosity, and adaptability are the essential traits for any scientist considering the leap into entrepreneurship.

Annelise was there on day one in 2000, when Immunocore spun out from Oxford University, and she’s been at the heart of the company’s pioneering work in T-cell receptor-based therapies ever since. She shares her story of building a new technology from scratch, the long road to Immunocore’s first approved drug, and how the company continues to evolve and innovate across oncology, infectious disease, and now autoimmunity.

We explore what it takes to lead through 25 years of change, how Immunocore maintained a unified culture through hypergrowth, and why curiosity, resilience, and purpose are the keys to a fulfilling scientific career.

Robert shares his unconventional path into Biotech - from working every entry-level job under the sun to returning to school in his thirties to study Biochemistry. Now leading a start-up while also working full-time in the lab at an early-stage Flagship Pioneering company, he reflects on the mindset needed to navigate entrepreneurship, the importance of mentorship, and why curiosity is more important than technical skills.

We also dive into the science behind Nanolyx’s unique nanoparticle-based technology, why they pivoted from FDA to EPA approval, and how the company is aiming to tackle everything from hospital infections to sustainability in surface disinfection.

Søren shares his journey from academic immunologist to biotech CEO, including pivotal moments in his career - from his experiences at the Pasteur Institute, to building his Biotech education at Symphogen, to navigating the corporate world at Novo Nordisk. He reflects on lessons learned from leadership, fundraising, and decision-making at the top, and the importance of humility, structure, and courage in the face of uncertainty.

We also explore what it really means to be a CEO, why "solving problems is your job," and how to strike the balance between hierarchy and creativity in growing Biotech companies.

A compelling conversation about resilience, reinvention, and leading with clarity in an ever-evolving industry.

Chelsea shares how her lifelong fascination with the brain and a PhD in neuroscience evolved into a career at the intersection of deep tech, healthcare, and entrepreneurship. From clinical trials and digital health to strategic partnerships and building a company from the ground up, her journey is a masterclass in adaptability, curiosity, and courage.

She also opens up about the mindset shifts required to become a first-time CEO, the importance of saying yes (even when you’re scared), and why meditation, martial arts, and mentorship have all shaped her leadership style.

Ulrika shares how a long-standing fascination with the immune system led her to discover Endothelin A2 as a key regulator of autoimmunity, and how that science laid the foundation for Serendo. She talks openly about the leap from scientist to CEO, the pressures of leadership, and what it really means to build something from scratch.

We also explore her time at Karolinska and Omnio, the importance of mentorship and networks, and why the best advice is to follow your gut - even if the path isn’t linear.

If you're curious about what it takes to spin out an idea into a company, balance passion with pressure, and lead with authenticity, this is one for you.

Jostein has spent over two decades in radionuclide therapy, taking discoveries from the lab to patients. Now, he's developing a new treatment for glioblastoma, one of the most aggressive and challenging brain cancers, using targeted radionuclide therapy derived from Norwegian seaweed.

We talk about his journey from academia to Biotech, the hard lessons of building and scaling a company, and why following the science, staying agile, and knowing when to walk away are critical in drug discovery.

Jostein also shares his experience of entrepreneurship in Biotech, the challenges of funding innovative treatments, and what’s next for Blue Wave as they move towards the clinic.

Karin’s career has taken her from a PhD in cardiovascular science to leadership roles in big pharma, business development, and drug discovery. Now, she oversees early-stage research, external innovation, and portfolio strategy at one of the world’s most successful pharmaceutical companies.

We discuss how Novo Nordisk has transformed over the past seven years, the importance of human-centric drug discovery, and why AI, external partnerships, and a more holistic approach to disease biology are shaping the future of the industry.

Tune in for brilliant insights on navigating an international career, the power of cross-disciplinary thinking, and why leadership in science requires both vision and adaptability.

The last five years have been transformative for Dave, from leading AI-driven drug discovery at Exscientia to navigating one of Biotech’s biggest IPOs and stepping into the CEO role in a challenging market. Now, he’s focused on proving that AI-designed medicines can deliver real impact, with clinical results beginning to emerge.

We discuss the evolution of AI in drug discovery, the lessons Dave has learned leading a publicly listed company, and why the industry must focus on reducing drug development failure rates to make new medicines more accessible.

A fascinating conversation with a leader at the forefront of Biotech innovation.

Mikko’s journey has taken him from academia to Biotech entrepreneurship, with more than 25 years in gene therapy. He shares the story behind RNatives, the challenges of launching a company in a tough funding climate, and the resilience required to keep going when setbacks arise.

Emma and Mikko talk about navigating the transition from scientist to entrepreneur, building a startup from the ground up, and the importance of networking, persistence, and adaptability in the Biotech world.

This episode offers a candid look at what it takes to turn breakthrough science into a thriving business.

Josef started out in academia, completing a PhD at Harvard Stem Cell Institute, before moving into consulting, venture capital, pharma, and Biotech startups. Now, he’s leading efforts to rejuvenate the immune system and combat age-related disease.

He shares his journey from scientist to business leader, the challenges of fundraising in today’s climate, and why mentorship, sponsorship, and big pharma experience can be game changers for those looking to enter Biotech.

Josef’s insights are essential listening for scientists, entrepreneurs, and anyone navigating career transitions in drug discovery.

Dominique takes us through her unconventional journey - from aspiring flight attendant to Biotech entrepreneur - sharing the pivotal moments that shaped her career. She talks about the challenges of leading a startup through uncertainty, balancing science and business as both CSO and CEO, and why strategic timing is key in career growth.

We also discuss the evolution of the dark genome field, NextRNA’s recent partnership with Bayer, and what’s next for this exciting company as it moves towards the clinic.

A fascinating conversation on leadership, resilience, and pushing the boundaries of biology.

Christian’s work focuses on developing immune tolerance therapies for autoimmune diseases, using nanoparticle technology to retrain the immune system. With Topas recently completing a Phase 2a trial in coeliac disease, he shares the excitement of leading a Biotech at a critical stage and the challenges of securing funding to drive the next phase of development.

He also reflects on his career journey from academia to Big Pharma and now Biotech, the lessons he’s learned from global leadership roles, and why stepping outside your comfort zone - sometimes into the “crazy” - can lead to the most rewarding opportunities.

If you're interested in the science behind immune tolerance, the transition from pharma to Biotech, and what it takes to navigate a career in life sciences, this is an episode you won’t want to miss.

Theonie’s work is all about uncovering ground-breaking biology and turning it into transformative Biotech companies. She shares her journey from academia to venture creation, her experience co-founding multiple Biotech start-ups, and how Prologue Medicines is harnessing viral proteins to develop innovative therapeutics.

She also dives into the importance of culture in scientific innovation, the role of mentorship in shaping careers, and why curiosity is the most powerful tool a scientist can have.

If you're interested in the intersection of cutting-edge science and entrepreneurship, the realities of Biotech leadership, and how to create an impact beyond the lab, this is an episode you won’t want to miss.

Riccardo shared his journey from academia to Biotech entrepreneurship, discussing how a serendipitous discovery during his postdoctoral research at Harvard led him to explore the role of microRNAs in metabolism. He delved into the challenges and rewards of founding Resalis Therapeutics, highlighting the importance of resilience in securing funding and the differences between academic and commercial science.

We also explored his perspectives on leadership, the value of collaboration, and the advice he would give to early-career scientists.

A compelling conversation about adaptability, perseverance, and the pursuit of translational science.

Graham shared how Quiver is combining stem cell models, optogenetics, and AI to study brain diseases at an unprecedented scale, and what he’s learned from spending over a decade growing within the same company, from Senior Scientist to CSO. We also explored the realities of Biotech growth, the challenges of translating research into real-world impact, and why persistence is key to success in this space.

A fascinating insight into the future of brain-targeted drug development.

Marco’s career has taken him from Biochemistry to Biotech start-ups, where he’s using causal inference to reshape clinical trials and drug development. We explored the evolution of AI in science, the rise of tech-bio companies, and why he believes this is the best time in history to be a scientist.

We also got into the mindset shift needed for scientists moving into business - and why failure isn’t just inevitable, but essential.

Join us for a really thought-provoking episode.

Tommi’s career has taken him from medicine and research to consulting at BCG and leadership roles in Biotech. He shared insights on GlyProVac’s work, why commercial thinking is key in drug development, and lessons from his time at Bavarian Nordic - including the unexpected rise of the MPOX vaccine.

His advice for scientists moving into industry? Start with the end in mind.

A great conversation on science, strategy, and the business of Biotech.

Martijn discussed the pivotal moments in his career, from a PhD at Oxford that sparked his passion for impactful science, to his tenure at Novo Nordisk, and ultimately to joining Cytoki Pharma. Along the way, he emphasised the importance of adaptability, the nuances of transitioning between academia and industry, and the role of networks and teamwork in achieving success.

With Cytoki Pharma approaching critical milestones in their clinical studies, Martijn also reflected on the challenges and excitement of developing ground-breaking treatments in a dynamic Biotech environment. Tune in for a conversation packed with advice on career growth, the evolution of drug discovery, and the human side of building innovative Biotech companies.

Jordi delved into his unconventional career path, including his foundational work in phenotypic drug discovery, insights on transitioning from academia to biotech, and the critical role of mentorship and networking in shaping his success. He also explored the transformative potential of AI in drug development, emphasising the importance of generating high-quality data to drive innovation.

Listen in for a brilliant conversation about leveraging technology to address unmet medical needs, and the power of adaptability in forging a meaningful career in science.

Henri reflects on his journey, from his early days in academic research to founding start-ups and leading Herantis’ mission to develop disease-modifying treatments. He talks about the importance of balancing scientific rigour with innovation, navigating the risks of challenging established dogmas, and the role personal passion plays in driving success.

This episode is packed with insights into the cutting edge of neurodegenerative research, the lessons learned from taking bold career steps, and the inspiration behind Henri’s dedication to improving patients’ lives. Tune in for an inspiring and thought-provoking conversation.

Emma and Arvid’s conversation delves into the evolution of Empros Pharma, the challenges of developing innovative treatments in a competitive field, and the critical importance of adapting to an ever-changing market landscape. Arvid also reflects on his career trajectory, discovering his leadership potential, and the value of seizing unexpected opportunities along the way.

A must-listen episode for biotech enthusiasts, aspiring leaders, and anyone passionate about making an impact in the life sciences industry.

Jonas shares his journey from academic Biophysics to Biotech leadership, reflecting on the importance of adaptability and continuous learning. We discuss Acousia’s groundbreaking work targeting sensory hair cells and their Phase 2 trial aimed at preventing chemotherapy-induced hearing loss, as well as the challenges and rewards of leading a lean, virtual Biotech.

An inspiring conversation about tackling a major global health issue and building a meaningful career in science.

David shares his unique career journey, from aspiring author to leading drug discovery programs at Pfizer and now in Biotech. He reflects on the power of curiosity, mentorship, and cross-disciplinary learning that shaped his path to leadership.

In this episode, David and Emma discuss Vigil's ground-breaking work in targeting ALSP and Alzheimer’s disease, the lessons he’s learned transitioning from big pharma to Biotech, and why having fun is essential to building a fulfilling scientific career.

Join us for an inspiring conversation about leadership, innovation, and advancing treatments for patients in need.

We also got to hear about Rodrigo’s incredible journey - from growing up in a small farming village in Portugal to leading cutting-edge biotech companies - all driven by his passion for cellular plasticity and the transformative potential of Yamanaka factors. Along the way, he reflects on the lessons he’s learned, balancing science and business, and why emphasis on execution is key.

Join us as we explore the science of rejuvenation, the innovation behind it, and the mindset needed to succeed in this ever-evolving field.

We also explored the game-changing potential of Precede’s work in epigenomics and how their innovative platform is helping to unlock the future of precision medicine. Along the way, Jen reflects on her passion for mentoring, the importance of fostering diversity, and how embracing your authentic style can drive both personal and professional success.

This is a conversation full of practical insights and inspiration for anyone navigating a career in science, leadership, or the life sciences industry.

Our conversation explores the challenges of early-stage entrepreneurship, the importance of surrounding yourself with the right people, and the transition from being a scientist at the bench to leading a multidisciplinary team. James also reflects on the role of focus, perseverance, and tackling unsolved problems in building a world-class biotech organisation.

A must-listen episode for aspiring founders, scientists, and anyone curious about the intersection of AI and biology.

Katie tells us all about the science behind their work, how her career has evolved (including 25 years at Oxford Biomedica), and why stepping out of your comfort zone and creating your own luck are so important.

It’s a brilliant conversation full of insights into leadership, innovation, and building something great on a shoestring budget.

Lucas opens up about his path from academia to industry, driven by a lifelong love of science and a desire to make a real difference in people’s lives. He talks about the unique challenges of his role, juggling hands-on lab work, strategic planning, and managing a small team in a high-stakes environment. He also reflects on the key skills he’s learned along the way—adaptability, risk-taking, and staying curious.

As CuraCell prepares to start its first clinical trials in 2025 Lucas gives us an inside look, sharing honest insights into making the shift from academic research to the fast-paced demands of industry. Join us this week for a thoughtful, inspiring conversation with a scientist at the cutting edge of cancer therapy.

Lindsay also highlights her role in mentoring the next generation of scientists and her team’s exciting plans for QVance, a new venture to support advanced therapies with robust quality analytics.

If you’re curious about the future of cell therapy, the real-world impact of innovative science, and a career built on passion and purpose, this is an episode you won’t want to miss.

Torleif takes us through Authera's journey from its academic beginnings in Oslo to becoming a revenue-generating company with a clear mission: to drive therapeutic innovation. He reflects on his path from molecular biology to biotech entrepreneurship, highlighting the power of curiosity, adaptability, and having the courage to bridge science and business.

If you're curious about making the leap from academia to biotech, or want to hear what it really takes to build a company with heart, tune in—you won’t want to miss this episode.

Christian opens up about the unexpected path that led him into the world of diagnostics and therapeutics, where he and his team are now using AI to uncover new possibilities for drug discovery and push the boundaries of what’s possible in healthcare. He shares some hard-earned lessons about curiosity, the importance of connecting with others, and finding your own unique strengths, whether you’re in a lab or building a business.

Join us for a thought-provoking discussion on embracing opportunities, following your interests, and letting curiosity guide you to places you never thought you'd end up.

Simon’s career has taken some fascinating twists and turns, from veterinary medicine to electrical engineering, and eventually into diagnostics, drug discovery and precision medicine.

He shares how those experiences have shaped his approach today, and how staying flexible, taking on new challenges and stepping out of your comfort zone have helped him to build an exciting career.

Adam shares the frustrations that led him to start his own company, explaining how his experiences in academia and industry shaped his vision. He talks about the challenge of scaling up stem cell manufacturing and how Unicorn Biotechnologies’ approach strips complex problems back to their fundamentals, making the whole process more efficient and accessible.

In a candid conversation, Adam also reflects on his personal journey—balancing his love of science with a growing entrepreneurial drive and learning from the highs and lows of start-up life. He offers advice for those thinking about making the leap from research to business, emphasising the importance of being driven by curiosity, embracing uncertainty, and continuously learning.

This episode is a must-listen for anyone interested in biotech innovation, entrepreneurship, and the real-world challenges of scaling scientific breakthroughs.

Volker also reflects on his career transitions, from leading Pfizer’s CNS Pain franchise to spearheading a service and solution business aimed at improving patient outcomes beyond pharmaceuticals. Throughout the discussion, he emphasizes the importance of authenticity, purpose, and impact in driving success within the biotech industry. He offers advice on maintaining a strong sense of urgency, fostering a purpose-driven culture, and how to navigate the difficult elements of leadership in a fast-paced environment.

Join us this week as we discuss the challenges and rewards of leading a biotech company with a focus on innovative patient-centric solutions.

Marcin also opens up about his personal journey into science, starting with a childhood surrounded by scientists and doctors, and how that led him into a career spanning structural biology, protein engineering, and ground-breaking start-ups like Grail and Arsenal Bio. He talks about the lessons he’s learned along the way, like the importance of staying curious, embracing technology, and being open to unexpected opportunities.

Join us for a fascinating discussion on the intersection of science, technology, and the evolving landscape of drug discovery.

Alistair opens up about the excitement and challenges of his new role, the importance of always looking ahead, and how he balances immediate priorities with long-term innovation. He also reflects on the pivotal moments in his career, from his unexpected entry into pharma to his deepening focus on making a real difference for patients.

Alistair offers honest and practical advice for those starting out in their scientific careers. He emphasizes the importance of staying curious, connecting with others, and being open to stepping out of your comfort zone. He also talks about the power of collaboration and how building a strong, open, and innovative culture has been key to his success at UCB.

If you’re interested in the human side of a career in science and what it takes to lead with purpose, this episode is full of insights from someone who’s done it all.

Kenny takes us through his incredible career journey, from his early passion for chemistry to becoming a leader in Boston’s thriving biotech industry. We discuss his work on RNA-modifying proteins and how his team is tackling the challenges of targeting complex biology with innovative chemistry.

In this episode, Kenny and I discuss the strategic thinking required to drive success in biotech, the importance of building strong, multidisciplinary teams, and the lessons he’s learned on his path from scientist to executive. He also shares valuable advice on following your passions and the importance of staying adaptable in a fast-changing industry.

Join us for a thought-provoking conversation with Kenny Duncan, where we unpack the future of drug discovery and the crucial role chemistry continues to play in shaping the industry.

Richard shares his fascinating career journey, from his early days as a Computational Chemist to his current role leading Business Development in one of the most innovative companies in drug discovery. He offers unique insights into how AI is not only accelerating the process but also increasing the likelihood of success in developing new therapies.

In this episode, Rich and I discuss the transformative potential of AI in drug discovery, explaining how these technologies are changing the game by improving the quality of molecules and enhancing the precision of clinical trials. He also reflects on the challenges of adapting to a rapidly evolving industry and the importance of staying open to new ideas and learning from those around you.

Join us for an inspiring conversation with Richard Law, where we delve into the future of drug discovery and the revolutionary role AI is set to play.

We explored Hazel's career path, her transition into a CEO role and her insights on leadership, the significance of networking, and balancing professional and personal life.

This week on Careers in Discovery, we welcome Jose Munoz-Olaya, Chief Scientific Officer of Valink Therapeutics.

Jose shares his journey from an eager intern to a leader in biotechnology, emphasizing the importance of mentorship and the power of teamwork. He discusses his role at Valink, where he's spearheading the development of next-generation Antibody-Drug Conjugates (ADCs) for oncology using their innovative high-throughput screening platform.

Join us as Jose discusses:

• His early inspiration from a high school science teacher and his diverse family background
• The critical milestones of his career, including his influential roles at Cambridge Antibody Technology, F-star, and Adaptate
• Lessons learned about the importance of building strong teams and fostering a culture of continuous learning
• His advice for aspiring scientists: trust your mentors, be patient, and remain open to learning

Tune in for all this, and much more....

Ben caught us up on what he's learned over the last five years, including why failing fast isn't a viable strategy in drug discovery, and introduced us to PhoreMost's brand new molecular glue platform, GlueSeeker.

Shane shared with us the story of his transition from academic to Biotech entrepreneur, why communication, persistence, collaboration and focus are critical skills for success, his amazing track record of securing grant funding, and much more.

Maude joined us on Careers in Discovery to talk about the impact of machine learning on drug development, taking control of her career by literally knocking on doors, balancing humility and confidence, and much more.

Vern's career has seen him travel the world, from the UK to Italy, China and the US, and he shared with us the key lessons he's learned along the way.

Jordan joined us to talk about building conviction, seeking feedback & maintaining networks, the huge opportunity lying in failed research, and why risk is relative in your career.

Bill joined us to talk about his career, the huge potential that still exists within antibody discovery and the magic of seeing a 96 well ELISA plate turn blue after months of failure!

Enjoy...

Namir joined us on Careers in Discovery to talk about when precision medicine gets too precise, the importance of servant leadership and trusting the journey in your career.

Enjoy!

Jane joined us to discuss that career, how she created a portfolio of NED positions, the real value of an MBA and whether you really need a PhD.

Enjoy!

Samantha Bailey-Bucktrout is the Senior Vice President of Research at Akamis Bio, a company harnessing the power of tumour gene therapy in the fight against cancer.

Samantha talked to us about her career in cancer immunotherapy, what Greek mythology has to do with modern-day Biotech, and the importance of a collaborative approach to drug development.

Enjoy!

Beverley Carr is the Chief Business & Operating Officer of Amphista Therapeutics, a company re-engineering TPD therapies to tackle cancer and neurological disorders.

Beverley joined us on Careers in Discovery to talk about how Amphista are tackling the limitations of first-generation TPDs, why strategic Business Development is coming back into fashion, and the qualities that make a good BD person.

Enjoy!

Janette Thomas has built a career from Researcher to Project Manager, Operations Director and now CEO of Five Alarm Bio, a company focused on novel approaches to anti-aging.

Janette joined us to talk about the current state of anti-aging research, what makes a good project manager and why you should never be limited by fear in your career.

Enjoy!

Dan Williams is the CEO of SynaptixBio, a company dedicated to developing lifesaving therapies for severe leukodystrophies.

Dan joined us to talk about the challenges of building a company around an ultra rare disease, why exposure to an executive team is critical for career development and what REALLY makes early stage Biotech companies successful.

Enjoy!

Matthew Duchars is the CEO of CHAIN Biotech, a fascinating company developing oral vaccines and immunotherapies that target the microbiome.

Matthew joined us to discuss the importance of culture and environment in delivering great science, how a career in vaccine development was set into motion by an encounter with a dead mole, and being at the heart of the UK vaccines ecosystem during the COVID pandemic.

Enjoy!

Orla Cunningham is the Chief Scientific Officer of Granular Therapeutics and Ultrahuman 8, companies developing novel single antibody therapies for a range of diseases.

Orla talked to us about her fascinating career to date, as well as the therapeutic potential of mast cells, how to get the best from your CRO partners and why communication is the most important skill scientists must develop.

Enjoy!

Rebecca Godfrey is the Chief Operating Officer of ExpressionEdits and the author of "The Leadership Vaccine".

Rebecca talked to us on Careers in Discovery about her journey from Immunology PhD to COO, figuring out who you are professionally and why she loves her job.

Enjoy!

Jenny Barnett is the CEO of Monument Therapeutics, a Biotech company using precision medicine approaches to develop new treatments for psychiatric and neurological conditions, and the Chief Scientific Officer of Five Lives, a digital therapeutics business focused on reducing dementia risk.

Jenny joined us on Careers in Discovery to discuss her career so far, why academia wasn't for her, how digital biomarkers can improve clinical trial performance and the things she had to learn to become an effective CEO.

Enjoy!

Paul Thompson is the Chief Scientific Officer of Mission Therapeutics, a company at the cutting edge of DUB inhibitor research to treat a range of conditions.

Paul talked to us about his career so far, how his background in clinical development has informed his approach to preclinical research, and how to choose between large and small companies at the start of your career.

Enjoy!

Andy Whiting is the CEO of Nevrargenics, a Biotech company spun out of his research at Durham University using dual-acting retinoic acid receptor modulators as a novel treatment for neurodegenerative diseases.

Andy talked to us about his decision to leave academia to run the company, how he knew when the research had the potential to become a real drug, and why uncertainty and risk shouldn't hold your career back.

Enjoy!

Ross Breckenridge is the CEO of Arjuna Therapeutics, a Biotech company working on a novel class of (very) small molecule treatments for cancer.

Ross joined us to talk about the founding of Arjuna, his career leading to that point, working with Patrick Vallance and how the experience of losing patients has shaped his approach to drug research.

Enjoy!

Jonathan Steckbeck is the CEO of Peptilogics, a Biotech company combining peptide biology and machine learning to recreate the future of peptide biologics.

Jonathan talked us through his career so far, how business and science are fundamentally related, why every decision is made on a continuum, and the challenge of letting go of control as a CEO.

Enjoy!

Steve Trim is the founder and Chief Scientific Officer of Venomtech, a truly unique company that helps Biotech researchers to work with venom-based assays.

Steve talked to us on Careers in Discovery about his journey building a remarkable company, how he learned to be an entrepreneur and business leader and his experience contributing to the Human Genome Project.

Enjoy!

Tomas Dias is the Chief Technology Officer at Mursla, a Biotech company using extracellular vesicles to develop next-generation liquid biopsy tests in service of their mission to offer life-saving clinical insights to patients and their medical teams.

Tomas talked to us about his path through his career so far, why reliability is underrated and the importance of hard work, as well as how a tennis injury made a clear career choice for him.

Enjoy!

Samantha Dale Strasser is the Chief Scientific Officer of Pepper Bio, the world's first transomic analysis company.

Samantha joined us in a fascinating discussion about her career to date and her experiences of building Pepper, developing cures with confidence and the differences between working in academic research and a startup Biotech.

Enjoy!

Nara Daubeney is the COO of Phaim, a Biotech company using antigenic immune modulation to treat diabetes and other conditions.

Nara joined us to talk about her transition from a successful medical career into the world of start-up Biotech, taking the immune system back to school and why the "fire in your belly" should be your guide.

Enjoy!

Richard Weaver is a consultant to Biotech companies on their drug development programmes, specialising in DMPK. Before becoming a consultant, Rich was the founder of XenoGesis, a CRO he successfully sold to Sygnature Discovery in 2020.

Rich talked to us about his career as a scientist and an entrepreneur, his formula for building a CRO and the advantages of organic growth.

Enjoy!

Nuno Madeira do Ó is the CEO of Reflection Therapeutics, a Biotech company harnessing the potential of Tregs to treat inflammatory diseases.

Nuno shared the story of his career so far, and among other things we discussed pivoting a Biotech into a new disease area, transitioning from research into commercial roles and how a children's cartoon inspired a career in Life Sciences.

Enjoy!